Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
152 entries « 1 of 16 »

Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, Bedke J, Rini BI

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Journal Article

Eur Urol, 85 (2), 2024.

| Links:

Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M

Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC

Journal Article

Can Urol Assoc J, 18 (2), 2024.

Abstract | Links:

Lemire F, Zhang M, Anderson P, Finelli A, Rendon RA, Tanguay S, Bansal R, Bhindi B, So AI, Pouliot F, Dean L, Mallick R, Lavallée LT, Breau RH

The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors

Journal Article

Can Urol Assoc J, 18 (2), 2024.

Abstract | Links:

Parmar A, Ghosh S, Sahgal A, Lalani AA, Hansen AR, Reaume MN, Wood L, Basappa NS, Heng DYC, Graham J, Kollmannsberger C, Soulières D, Breau RH, Tanguay S, Kapoor A, Pouliot F, Bjarnason GA

Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma

Journal Article

Cancer Rep (Hoboken), 6 (3), 2023.

Abstract | Links:

Tremblay S, Alhogbani M, Weickhardt A, Davis ID, Scott AM, Hicks RJ, Metser U, Chua S, Davda R, Punwani S, Payne H, Tunariu N, Ho B, Young S, Singbo MNU, Bauman G, Emmett L, Pouliot F

Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial

Journal Article

Cancer Imaging, 23 (1), 2023.

Abstract | Links:

Millan B, Breau RH, Mallick R, Wood L, Rendon R, Finelli A, So AI, Lavallée LT, Pouliot F, Bhindi B, Heng D, Drachenberg D, Tanguay S, Dean L, Basappa NS, Lattouf JB, Bjarnason G, Lalani AK, Kapoor A

Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population

Journal Article

Urol Oncol, 41 (7), 2023.

Abstract | Links:

Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, Shum M, Lambert JP, Pouliot F, Pelletier M, Audet-Walsh É

Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer

Journal Article

Mol Oncol, 17 (10), 2023.

Abstract | Links:

Sawaya GB, Dragomir A, Wood LA, Kollmannsberger C, Basappa NS, Kapoor A, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Tanguay S

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Journal Article

Eur Urol Oncol, 2023.

Abstract | Links:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Journal Article

Cancer Lett, 553 , 2023.

Abstract | Links:

Beck J, Rouleau M, Lemire F, Neveu B, Déry M, Thériault B, Dubois G, Guérette D, Pouliot F

Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy

Journal Article

Prostate, 83 (7), 2023.

Abstract | Links:

152 entries « 1 of 16 »
Signaler des ajouts ou des modifications

Active projects

  • 3TMPO (Triple-Tracer strategy against Metastatic PrOstate cancer), from 2018-03-07 to 2024-03-31
  • Four-Timepoint Multi-tracer PET imaging to characterize metastatic PrOstate Cancer heterogeneity impact on treatment resistance in subjects beginning a new line of therapy, from 2023-03-31 to 2025-03-31
  • Surveillance of Complex Renal Cysts: The SOCRATIC study, from 2019-10-01 to 2028-09-30
  • Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
  • Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities, from 2022-10-01 to 2027-09-30

Recently finished projects

  • A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease , from 2021-04-01 to 2022-03-31
  • Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2023-12-15
  • Imagerie moléculaire relié au cancer de la prostate, from 2023-02-01 to 2024-01-31
  • National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2023-06-30
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, from 2019-07-01 to 2023-06-30
Data provided by the Université Laval research projects registery